News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,733 Results
Type
Article (44755)
Company Profile (289)
Press Release (694673)
Multimedia
Podcasts (106)
Webinars (20)
Section
Business (206245)
Career Advice (2048)
Deals (35804)
Drug Delivery (131)
Drug Development (82617)
Employer Resources (173)
FDA (16722)
Job Trends (15114)
News (349674)
Policy (33006)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2688)
Accelerated approval (49)
Adcomms (28)
Allergies (171)
Alliances (50055)
ALS (223)
Alzheimer's disease (1906)
Antibody-drug conjugate (ADC) (448)
Approvals (17098)
Artificial intelligence (670)
Autoimmune disease (298)
Automation (56)
Bankruptcy (364)
Best Places to Work (11735)
BIOSECURE Act (20)
Biosimilars (222)
Biotechnology (189)
Bladder cancer (195)
Brain cancer (73)
Breast cancer (752)
Cancer (5854)
Cardiovascular disease (473)
Career advice (1737)
Career pathing (42)
CAR-T (336)
CDC (58)
Celiac Disease (3)
Cell therapy (912)
Cervical cancer (47)
Clinical research (71616)
Collaboration (2090)
Company closure (6)
Compensation (1403)
Complete response letters (86)
COVID-19 (2765)
CRISPR (109)
C-suite (1143)
Cystic fibrosis (152)
Data (7972)
Decentralized trials (3)
Denatured (28)
Depression (179)
Dermatology (86)
Diabetes (590)
Diagnostics (6959)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (323)
Drug pricing (203)
Drug shortages (31)
Duchenne muscular dystrophy (290)
Earnings (92407)
Editorial (69)
Employer branding (21)
Employer resources (152)
Events (120670)
Executive appointments (1090)
FDA (20495)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1759)
Gene editing (237)
Generative AI (56)
Gene therapy (744)
GLP-1 (1068)
Government (4773)
Grass and pollen (6)
Guidances (408)
Healthcare (19178)
HIV (80)
Huntington's disease (62)
IgA nephropathy (97)
Immunology and inflammation (295)
Immuno-oncology (93)
Indications (194)
Infectious disease (3104)
Inflammatory bowel disease (219)
Inflation Reduction Act (14)
Influenza (138)
Intellectual property (292)
Interviews (323)
IPO (16752)
IRA (50)
Job creations (3683)
Job search strategy (1441)
JPM (63)
Kidney cancer (19)
Labor market (101)
Layoffs (569)
Leadership (41)
Legal (8000)
Liver cancer (100)
Longevity (33)
Lung cancer (770)
Lymphoma (431)
Machine learning (60)
Management (59)
Manufacturing (1054)
MASH (190)
Medical device (14152)
Medtech (14278)
Mergers & acquisitions (20305)
Metabolic disorders (1518)
mRNA (209)
Multiple sclerosis (191)
NASH (17)
Neurodegenerative disease (467)
Neuropsychiatric disorders (116)
Neuroscience (3528)
Neurotech (2)
NextGen: Class of 2026 (6600)
Non-profit (4583)
Now hiring (78)
Obesity (713)
Opinion (293)
Ovarian cancer (220)
Pain (266)
Pancreatic cancer (306)
Parkinson's disease (390)
Partnered (33)
Patents (598)
Patient recruitment (676)
Peanut (62)
People (60111)
Pharmaceutical (61)
Pharmacy benefit managers (33)
Phase 1 (22325)
Phase 2 (31554)
Phase 3 (23458)
Pipeline (8844)
Policy (323)
Postmarket research (2614)
Preclinical (9591)
Press Release (64)
Prostate cancer (307)
Psychedelics (58)
Radiopharmaceuticals (327)
Rare diseases (1108)
Real estate (6018)
Recruiting (70)
Regulatory (25665)
Reports (56)
Research institute (2493)
Resumes & cover letters (354)
Rett syndrome (40)
RNA editing (24)
RSV (88)
Schizophrenia (184)
Series A (297)
Series B (220)
Service/supplier (11)
Sickle cell disease (112)
Special edition (30)
Spinal muscular atrophy (181)
Sponsored (48)
Startups (3693)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (76)
Vaccines (1104)
Venture capital (109)
Weight loss (459)
Women's health (128)
Worklife (20)
Date
Today (171)
Last 7 days (818)
Last 30 days (3658)
Last 365 days (30542)
2026 (12837)
2025 (30537)
2024 (35572)
2023 (40406)
2022 (51555)
2021 (56099)
2020 (54412)
2019 (46962)
2018 (35378)
2017 (32510)
2016 (31994)
2015 (38009)
2014 (31764)
2013 (26991)
2012 (29094)
2011 (29659)
2010 (27715)
Location
Africa (746)
Alabama (93)
Alaska (7)
Arizona (351)
Arkansas (14)
Asia (40211)
Australia (6655)
California (13362)
Canada (3785)
China (1368)
Colorado (569)
Connecticut (581)
Delaware (410)
Europe (88114)
Florida (2003)
Georgia (432)
Hawaii (3)
Idaho (62)
Illinois (1072)
India (90)
Indiana (603)
Iowa (23)
Japan (544)
Kansas (132)
Kentucky (51)
Louisiana (43)
Maine (76)
Maryland (1597)
Massachusetts (9636)
Michigan (374)
Minnesota (723)
Mississippi (7)
Missouri (145)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3518)
New Mexico (30)
New York (3515)
North Carolina (1700)
North Dakota (9)
Northern California (6695)
Ohio (401)
Oklahoma (23)
Oregon (41)
Pennsylvania (2690)
Puerto Rico (29)
Rhode Island (50)
South America (1126)
South Carolina (86)
South Dakota (2)
Southern California (5276)
Tennessee (214)
Texas (2128)
United States (47297)
Utah (399)
Vermont (1)
Virginia (324)
Washington D.C. (82)
Washington State (1068)
West Virginia (4)
Wisconsin (126)
Wyoming (2)
739,733 Results for "alzamend neuro inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study in a Trial Conducted at Massachusetts General Hospital
April 7, 2026
·
8 min read
Press Releases
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
March 26, 2026
·
8 min read
Press Releases
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 “Lithium in Brain” Study Conducted at Massachusetts General Hospital
November 20, 2025
·
5 min read
Press Releases
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
July 29, 2025
·
5 min read
Press Releases
Alzamend Neuro Announces Reverse Stock Split
May 8, 2025
·
4 min read
Press Releases
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
July 23, 2025
·
6 min read
Policy
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro, Inc. announced that the Nasdaq Hearings Panel granted Alzamend’s request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550, which requires stockholder equity of at least $2.5 million, and satisfying all applicable requirements for continued listing on Nasdaq.
May 22, 2024
·
3 min read
Press Releases
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
June 16, 2025
·
4 min read
BioMidwest
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced that it closed upon the initial tranche of a private placement pursuant to the Securities Purchase Agreement with an institutional investor.
May 14, 2024
·
5 min read
Press Releases
ClearPoint Neuro Reports First Quarter 2026 Results
May 14, 2026
·
16 min read
1 of 73,974
Next
